Make DORIBAX® your carbapenem for patients with cUTI, including pyelonephritis*1
Patients with cUTI, including pyelonephritis
In a subset analysis: Excellent clinical cure rates in severe or “high risk” cUTI populations1
Patients over 65 years old1
Patients with renal impairment†1
The Phase 3 comparative trial of adults with cUTI, including pyelonephritis, was a multicenter, prospective, randomized, double-blind study comparing DORIBAX® to levofloxacin.1
- DORIBAX®: 500 mg q8h (10-14 days) IV over 1 h; levofloxacin: 250 mg q24h (10-14 days) IV over 1 h
- Primary endpoint: Microbiological cure (complete eradication of all baseline pathogens) at the test-of-cure (TOC) visit (5-11 days after completing therapy) in microbiologically evaluable (ME) patients 95% Cl (-8.0%, 5.5%)
* Caused by susceptible strains of E coli (including cases with concurrent bacteremia), K pneumoniae, P mirabilis, P aeruginosa, or A baumannii.
† Subjects with renal impairment were identified as having creatinine clearance of less than 80 mL/min.
Explore the proven clinical efficacy of DORIBAX® for patients with cIAI.
Please see Indications and Important Safety Information below.